Your browser doesn't support javascript.
loading
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
Oda, Yoshiaki; Kumagai, Yuji; Kanai, Manabu; Iwama, Yasuhiro; Okura, Iori; Minamida, Takeshi; Yagi, Yukihiro; Kurosawa, Toru; Chivukula, Pad; Zhang, Ye; Walson, Judd L.
Afiliação
  • Oda Y; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Kumagai Y; Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan.
  • Kanai M; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Iwama Y; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Okura I; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Minamida T; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Yagi Y; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Kurosawa T; Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
  • Chivukula P; Arcturus Therapeutics, San Diego, CA, USA.
  • Zhang Y; Arcturus Therapeutics, San Diego, CA, USA.
  • Walson JL; Walson Consulting, Seattle, WA 98117, USA. Electronic address: jwalson@walsonconsultingllc.com.
Lancet Infect Dis ; 24(4): 341-343, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38310906
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Vacina BNT162 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Vacina BNT162 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article